The blockade of immune checkpoints in cancer immunotherapy

Pardoll, Drew M.·2012·Nature Reviews Cancer

DOI 10.1038/nrc3239

Cited by (1,122)

Items 101–200 of 1,122

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor, Alice Tsang Shaw, Lecia Van Dam Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea E. Fulton, Katherine R. Schultz et al. · 2016 · Clinical Cancer Research
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke, Keith T. Flaherty, Antoni Ribas, Georgina Venetia Long · 2017 · Nature Reviews Clinical Oncology
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay, Shohei Koyama, Julián Carretero, Abigail B. Altabef, Jeremy H. Tchaicha, Camilla Laulund Christensen, Oliver R. Mikse, Andrew D. Cherniack, Ellen M. Beauchamp, Trevor J. Pugh et al. · 2013 · Cancer Discovery
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina Venetia Long, Ana Maria Arance, Jean‐Jacques Grob, Laurent Mortier, ADIL I. DAUD, Matteo Salvatore Carlino, Catriona M. McNeil, Michal Lotem et al. · 2017 · The Lancet
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, Dongjun, Kryczek, Ilona, Nagarsheth, Nisha, Zhao, Lili, Wei, Shuang, Wang, Weimin, Sun, Yuqing, Zhao, Ende, Vatan, Linda, Szeliga, Wojciech et al. · 2015 · Nature
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, Catarina, Mendes, Rita, Baptista, Pedro V., Fernandes, Alexandra R. · 2019 · International Journal of Molecular Sciences
Immune cell promotion of metastasis
Kitamura, Takanori, Qian, Bin-Zhi, Pollard, Jeffrey W. · 2015 · Nature Reviews Immunology
Tertiary lymphoid structures in cancer
Ton N. Schumacher, Daniela S. Thommen · 2022 · Science
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, Shuang, Xu, Linping, Yi, Ming, Yu, Shengnan, Wu, Kongming, Luo, Suxia · 2019 · Molecular Cancer
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang, Jiacheng Bi, Xiaodong Zheng, Yongyan Chen, Hua Wang, Wenyong Wu, Zhengguang Wang, Qiang Wu, Hui Chin Peng, Haiming Wei et al. · 2018 · Nature Immunology
Non-small-cell lung cancer
Cesare Gridelli, Antônio Rossi, David Paul Carbone, Juliana Guarize, Niki Karachaliou, Tony S.K. Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell · 2015 · Nature Reviews Disease Primers
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Talia Golan, Dung Thi Le, Barbara Ann Burtness et al. · 2016 · The Lancet Oncology
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Barroso-Sousa, Romualdo, Barry, William T., Garrido-Castro, Ana C., Hodi, F. Stephen, Min, Le, Krop, Ian E., Tolaney, Sara M. · 2018 · JAMA Oncology
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, Aritraa, Maji, Avik, Potdar, Pravin D., Singh, Navneet, Parikh, Purvish, Bisht, Bharti, Mukherjee, Anubhab, Paul, Manash K. · 2023 · Molecular Cancer
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia‐Wei Li, Seung‐Oe Lim, Weiya Xia, Heng‐Huan Lee, Li-Chuan Chan, Chu‐Wei Kuo, Kay‐Hooi Khoo, Shih-Shin Chang, Jong‐Ho Cha, Tae‐Wan Kim et al. · 2016 · Nature Communications
Breast cancer: pathogenesis and treatments
Xin Xiong, Lewei Zheng, Yu‐Qiang Ding, Yufei Chen, Yuwen Cai, Leiping Wang, Liang Huang, Cuicui Liu, Zhi‐Ming Shao, Ke‐Da Yu · 2025 · Signal Transduction and Targeted Therapy
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros, Ahmad A. Tarhini, Émilie Routier, Olivier Lambotte, François Le Roy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurélien Marabelle, Stéphane Champiat, Armandine Berdelou et al. · 2016 · Nature Reviews Clinical Oncology
Targeting the tumour stroma to improve cancer therapy
Valkenburg, Kenneth C., de Groot, Amber E., Pienta, Kenneth J. · 2018 · Nature Reviews Clinical Oncology
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, Gregory L., Gladney, Whitney L. · 2015 · Clinical Cancer Research
The immunology of hepatocellular carcinoma
Ringelhan, Marc, Pfister, Dominik, O’Connor, Tracy, Pikarsky, Eli, Heikenwalder, Mathias · 2018 · Nature Immunology
TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment
Dongqing Sun, Jin Wang, Ya Han, Xin Dong, Jun Ge, Rongbin Zheng, Xiaoying Shi, Binbin Wang, Ziyi Li, Pengfei Ren et al. · 2020 · Nucleic Acids Research
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, Andrew D., June, Carl H., Levine, Bruce L. · 2016 · Nature Reviews Cancer
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, Antoni, Hamid, Omid, Daud, Adil, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S. et al. · 2016 · JAMA
Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11
Xueting Lang, Michael D. Green, Weimin Wang, Jiali Yu, Jae Eun Choi, Long Jiang, Peng Liao, Jiajia Zhou, Qiang Zhang, Ania Dow et al. · 2019 · Cancer Discovery
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia Chiara Formenti, Sandra Demaria · 2013 · JNCI Journal of the National Cancer Institute
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer et al. · 2016 · Immunity
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Xiaopin Duan, Christina Chan, Wenbin Lin · 2018 · Angewandte Chemie International Edition
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Mlecnik, Bernhard, Bindea, Gabriela, Angell, Helen K., Maby, Pauline, Angelova, Mihaela, Tougeron, David, Church, Sarah E., Lafontaine, Lucie, Fischer, Maria, Fredriksen, Tessa et al. · 2016 · Immunity
Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
Edward W. Roberts, Miranda L. Broz, Mikhail Binnewies, Mark B. Headley, Amanda E. Nelson, Denise M. Wolf, Tsuneyasu Kaisho, Dusan Bogunovic, Nina Bhardwaj, Matthew F. Krummel · 2016 · Cancer Cell
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, Mizuki, Ramaiya, Nikhil H., Hatabu, Hiroto, Hodi, F. Stephen · 2017 · Nature Reviews Clinical Oncology
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Qian Chen, Chao Wang, Xudong Zhang, Guojun Chen, Quanyin Hu, Hongjun Li, Jinqiang Wang, Di Wen, Yuqi Zhang, Yifei Lü et al. · 2018 · Nature Nanotechnology
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, Wei, Bai, Yibing, Xiong, Ying, Zhang, Jin, Chen, Shuokai, Zheng, Xiaojun, Meng, Xiangbo, Li, Lunyi, Wang, Jing, Xu, Chenguang et al. · 2016 · Nature
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada, Yosuke Togashi, Christopher Tay, Danbee Ha, Akinori Sasaki, Yoshiaki Nakamura, Eiichi Sato, Shota Fukuoka, Yasuko Tada, Atsushi Tanaka et al. · 2019 · Proceedings of the National Academy of Sciences
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, Moshe, Jiao, Yunxin J., Chen, Jonathan H., Rooney, Michael S., Barzily-Rokni, Michal, Eliane, Jean-Pierre, Bjorgaard, Stacey L., Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M. et al. · 2017 · Nature Communications
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Lesokhin, Alexander M., Ansell, Stephen M., Armand, Philippe, Scott, Emma C., Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M., Cohen, Adam D., Schuster, Stephen J., Lebovic, Daniel et al. · 2016 · Journal of Clinical Oncology
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Hegde, Priti S., Karanikas, Vaios, Evers, Stefan · 2016 · Clinical Cancer Research
Tackling the cancer stem cells — what challenges do they pose?
Diwakar Ram Pattabiraman, Robert A. Weinberg · 2014 · Nature Reviews Drug Discovery
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, Douglas B., Nebhan, Caroline A., Moslehi, Javid J., Balko, Justin M. · 2022 · Nature Reviews Clinical Oncology
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, José Ignacio Riezu‐Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe et al. · 2013 · Journal of Hepatology
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Dominic P. Del Re, Dulguun Amgalan, Andreas Linkermann, Qinghang Liu, Richard N. Kitsis · 2019 · Physiological Reviews
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte · 2019 · Journal of Experimental & Clinical Cancer Research
ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy
Ya‐Ru Miao, Qiong Zhang, Qian Lei, Mei Luo, Gui‐Yan Xie, Hongxiang Wang, An‐Yuan Guo · 2020 · Advanced Science
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Davis, Andrew A., Patel, Vaibhav G. · 2019 · Journal for ImmunoTherapy of Cancer
Cancer nanomedicine for combination cancer immunotherapy
Jutaek Nam, Sejin Son, Kyong Soo Park, Weiping Zou, Lonnie D. Shea, James Jaehyun Moon · 2019 · Nature Reviews Materials
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, Mark J., Ngiow, Shin Foong, Ribas, Antoni, Teng, Michele W. L. · 2016 · Nature Reviews Clinical Oncology
TGFβ biology in cancer progression and immunotherapy
Derynck, Rik, Turley, Shannon J., Akhurst, Rosemary J. · 2021 · Nature Reviews Clinical Oncology
Current Challenges in Cancer Treatment
Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis G Paz-Ares · 2016 · Clinical Therapeutics
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng, Wen Jiang, Betty Y.S. Kim, Cheng Cheng Zhang, Yang‐Xin Fu, Irving L. Weissman · 2019 · Nature reviews. Cancer
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou, Mauricio Burotto · 2015 · Journal of Clinical Oncology
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
Kumagai, Shogo, Koyama, Shohei, Itahashi, Kota, Tanegashima, Tokiyoshi, Lin, Yi-tzu, Togashi, Yosuke, Kamada, Takahiro, Irie, Takuma, Okumura, Genki, Kono, Hidetoshi et al. · 2022 · Cancer Cell
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Lu, Haiying, Zhou, Qiaodan, He, Jun, Jiang, Zhongliang, Peng, Cheng, Tong, Rongsheng, Shi, Jianyou · 2020 · Signal Transduction and Targeted Therapy
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Michele W.L. Teng, Edward P. Bowman, Joshua J. McElwee, Mark John Smyth, Jean‐Laurent Casanova, Andrea May Cooper, Daniel J Cua · 2015 · Nature Medicine
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens · 2017 · Clinical Cancer Research
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, Karolina, Banchereau, Jacques · 2013 · Immunity
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David Robert Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin B. Steins, Elena V Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis G Paz-Ares et al. · 2017 · Journal of Clinical Oncology
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Ann Burtness, Se‐Hoon Lee et al. · 2016 · Journal of Clinical Oncology
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, Mei Yi, Bo Xiang · 2024 · Molecular Cancer
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja, Kathleen A. McGuire, Robert T. Manguso, Martin W. LaFleur, Natalie Bucheimer Collins, W. Nicholas Haining, Gordon James Freeman, Arlene H. Sharpe · 2017 · The Journal of Experimental Medicine
Monoclonal Antibodies in Cancer Therapy
David J. Zahavi, Louis M. Weiner · 2020 · Antibodies
The Basis of Oncoimmunology
Palucka, A. Karolina, Coussens, Lisa M. · 2016 · Cell
Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer
Massard, Christophe, Gordon, Michael S., Sharma, Sunil, Rafii, Saeed, Wainberg, Zev A., Luke, Jason, Curiel, Tyler J., Colon-Otero, Gerardo, Hamid, Omid, Sanborn, Rachel E. et al. · 2016 · Journal of Clinical Oncology
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Desirée Schubert, Claudia Bode, Rupert Kenefeck, Tie Zheng Hou, James B. Wing, Alan Kennedy, Alla Bulashevska, Britt‐Sabina Petersen, Alejandro A. Schäffer, Björn Andreas Grüning et al. · 2014 · Nature Medicine
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
Joseph Francis McLaughlin, Gang Han, Kurt Alex Schalper, Daniel Carvajal‐Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy S. Herbst, Patricia Mucci LoRusso, David L. Rimm · 2015 · JAMA Oncology
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens, Gary Middleton · 2015 · Cancer Immunology Research
Treatment of renal cell carcinoma: Current status and future directions
Pedro Coelho Barata, Brian I. Rini · 2017 · CA A Cancer Journal for Clinicians
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R. et al. · 2019 · Annals of Oncology
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona A. Hendry, Roberto Salgado, Thomas Gevaert, Prudence Anne Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen K Van de Vijver, Monica Valeria Estrada, Paula I. González Ericsson et al. · 2017 · Advances in Anatomic Pathology
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian Andres Marin-Acevedo, Bhagirathbhai Dholaria, Aixa Elena Soyano, Keith L. Knutson, Saranya Chumsri, Yanyan Lou · 2018 · Journal of Hematology & Oncology
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yuting Chen, Kepan Chen, Na Fan, Wen Xiao, Qian Zheng, Guohong Li, Yuqin Teng, Min Wu et al. · 2022 · Signal Transduction and Targeted Therapy
The burgeoning family of unconventional T cells
Dale Ian Godfrey, Adam P. Uldrich, James McCluskey, Jamie Rossjohn, David Branch Moody · 2015 · Nature Immunology
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Nai‐Kong V. Cheung, Michael A. Dyer · 2013 · Nature reviews. Cancer
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics
Yunxia Wang, Song Zhang, Fengcheng Li, Ying Zhou, Ying Zhang, Zhengwen Wang, Runyuan Zhang, Jiang Zhu, Yuxiang Ren, Ying Ching Tan et al. · 2019 · Nucleic Acids Research
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, Seung-Oe, Li, Chia-Wei, Xia, Weiya, Cha, Jong-Ho, Chan, Li-Chuan, Wu, Yun, Chang, Shih-Shin, Lin, Wan-Chi, Hsu, Jung-Mao, Hsu, Yi-Hsin et al. · 2016 · Cancer Cell
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Chao Wang, Yanqi Ye, Gabrielle M. Hochu, Hasan Sadeghifar, Zhen Gu · 2016 · Nano Letters
The role of myeloid cells in cancer therapies
Engblom, Camilla, Pfirschke, Christina, Pittet, Mikael J. · 2016 · Nature Reviews Cancer
PD-L1 expression in human cancers and its association with clinical outcomes
Yu, Jinming, Wang, Xin, Teng, Feifei, Kong, Li · 2016 · OncoTargets and Therapy
Opportunities and challenges of radiotherapy for treating cancer
Schaue, Dörthe, McBride, William H. · 2015 · Nature Reviews Clinical Oncology
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
Zhang, Yuanyuan, Chen, Hongyan, Mo, Hongnan, Hu, Xueda, Gao, Ranran, Zhao, Yahui, Liu, Baolin, Niu, Lijuan, Sun, Xiaoying, Yu, Xiao et al. · 2021 · Cancer Cell
Therapeutic vaccines for cancer: an overview of clinical trials
Ignacio Melero, Gustav Gaudernack, Winald R. Gerritsen, Christoph Huber, Giorgio Parmiani, Suzy Scholl, Nicholas J. Thatcher, John Wagstaff, Christoph Carl Zielinski, Ian Faulkner et al. · 2014 · Nature Reviews Clinical Oncology
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong‐Ho Cha, Wenhao Yang, Weiya Xia, Yongkun Wei, Li-Chuan Chan, Seung‐Oe Lim, Chia-Wei Li, Tae‐Wan Kim, Shih-Shin Chang, Heng‐Huan Lee et al. · 2018 · Molecular Cell
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, Jiehui, Wang, Eric S., Jenkins, Russell W., Li, Shuai, Dries, Ruben, Yates, Kathleen, Chhabra, Sandeep, Huang, Wei, Liu, Hongye, Aref, Amir R. et al. · 2018 · Cancer Discovery
Cell death-based treatment of lung adenocarcinoma
Denisenko, Tatiana V., Budkevich, Inna N., Zhivotovsky, Boris · 2018 · Cell Death & Disease
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L. · 2014 · Science Translational Medicine
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
O’Reilly, Eileen M., Oh, Do-Youn, Dhani, Neesha, Renouf, Daniel J., Lee, Myung Ah, Sun, Weijing, Fisher, George, Hezel, Aram, Chang, Shao-Chun, Vlahovic, Gordana et al. · 2019 · JAMA Oncology
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C.C., Jin, L., Zhang, X.D. · 2016 · Annals of Oncology
Tumor-Derived Exosomes and Their Role in Cancer Progression
Theresa L. Whiteside · 2016 · Advances in clinical chemistry
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter, Greg A. Lazar · 2017 · Nature Reviews Drug Discovery
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher Mitchell Jackson, John Hyunkuk Choi, Michael K. Lim · 2019 · Nature Immunology
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
D'Angelo, Sandra P, Mahoney, Michelle R, Van Tine, Brian A, Atkins, James, Milhem, Mohammed M, Jahagirdar, Balkrishna N, Antonescu, Cristina R, Horvath, Elise, Tap, William D, Schwartz, Gary K et al. · 2018 · The Lancet Oncology
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
Chunbai He, Xiaopin Duan, Nining Guo, Christina Chan, Christopher J. Poon, Ralph R. Weichselbaum, Wenbin Lin · 2016 · Nature Communications
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, Moriah E., Placone, Amanda L., Wong, Andrew D., Xu, Zinnia S., Searson, Peter C. · 2016 · Frontiers in Bioengineering and Biotechnology
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, Joel, Sun, Haoyu, Welling, Theodore H, Tian, Zhigang, Zou, Weiping · 2013 · Current Opinion in Immunology
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, Joerg · 2020 · Nature Reviews Cardiology
PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov, Maria Themeli, Michel Sadelain · 2013 · Science Translational Medicine
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
Martin Reck, Klaus Friedrich Rabe · 2017 · New England Journal of Medicine
Building better monoclonal antibody-based therapeutics
George J. Weiner · 2015 · Nature reviews. Cancer
A microfluidic device for label-free, physical capture of circulating tumor cell clusters
Ali Fatih Sarioglu, Nicola Aceto, Nikola Kojić, Maria Donaldson Collier, Mahnaz Zeinali, Bashar M. Hamza, Amanda Engstrom, Huili Zhu, Tilak Kumar Sundaresan, David Tomoaki Miyamoto et al. · 2015 · Nature Methods
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Ebert, Peter J.R., Cheung, Jeanne, Yang, Yagai, McNamara, Erin, Hong, Rebecca, Moskalenko, Marina, Gould, Stephen E., Maecker, Heather, Irving, Bryan A., Kim, Jeong M. et al. · 2016 · Immunity
Wnt/beta-catenin pathway: modulating anticancer immune response
Sachin Gopalkrishna Pai, Benedito A. Carneiro, José Maurício Mota, Ricardo Borges da Costa, Caio A. Leite, Romualdo Barroso‐Sousa, Jason Benjamin Kaplan, Young Kwang Chae, Francis Joseph Giles · 2017 · Journal of Hematology & Oncology
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona A. Hendry, Roberto Salgado, Thomas Gevaert, Prudence Anne Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen K Van de Vijver, Monica Valeria Estrada, Paula I. González Ericsson et al. · 2017 · Advances in Anatomic Pathology